Breaking News
Vance: Federal Government Has Identified $230 Billion In Fraud Since March
Saudi Arabia's $5 Oil Detour Is Expensive... But Worth It
Why Gen Z is the New Silent Generation
Can't come to Anarchapulco? Try Liberpulco
Top Tech News
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
CBD Bombshell:
This is huge. The FDA just granted orphan drug designation (ODD) to Insys Therapeutics for its pharmaceutical-grade, proprietary cannabidiol (CBD) product for treating cancer tumors in humans. Although glioma tumors affect less than 200,000 Americans, this FDA approval sets a precedent for natural remedies, and could lead to a revolutionary way to legally treat many forms of cancer with natural cures. In justifying preliminary approval of utilizing CBD to treat brain and spinal cancer tumors of this kind, Insys Therapeutics provided the FDA with the scientific rationale for CBD's benefits, including human experiences with the natural remedy, evidence discovered through in vitro studies, and preclinical animal testing.